HANGZHOU, CHINA, (October 31, 2025) – HighField Biopharmaceuticals, a clinical stage company using lipid-based  therapeutics to treat cancer and other diseases, announced today it will make Late Breaking Abstract Presentations on two of its novel immuno-oncology drugs at the Society for Immunotherapy of Cancer (SITC) 40^日 Anniversary Meeting November 5 – 9, 2025, in National Harbor, MD.

“We are very encouraged that SITC chose to recognize the significance of our attempts to develop next generation immunotherapies,” said HighField CEO and Scientific Founder Yuhong Xu. “We are leading the development of lipid-based products that focus on the different aspects of T cell modulation in the tumor microenvironment.”

Dr. Xu explained, “HF1K16 and HF50 are part of a pipeline of products derived from our lipid-based therapeutic platforms. They represent a new vision for cancer immunotherapy treatment designed to generate better outcomes for more patients. This pipeline also includes HFG2 based on our platform of TCTplex for T cell gene editing to create 体内 CAR T cells.”

The abstract 数字 1314, titled First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response, will be presented Saturday, Nov. 8.

The abstract Number 1350, titled Targeting MDSCs with HF1K16 Unlocks Long-term Survival in Refractory Recurrent Glioma; an update of NCT05388487, will be presented Saturday, Nov. 8.

关于 HighField 生物制药

Highfield 是一家临床阶段公司，专注于针对免疫肿瘤学和基因治疗的脂质体结构的新应用。HighField 在临床试验中的主导产品是 K1，源自其 ADCplex^商标 平台，随后是 HF50，源自其 TCEplex^商标 平台。该公司的产品线还包括 K16，一种药物包裹的免疫调节脂质体，靶向骨髓来源的抑制细胞，用于难治性癌症的临床试验；以及源自其 tLNPplex™ 平台的 HFG1，用于 GLP-1R 激动剂的 mRNA 表达，用于减肥和治疗糖尿病。有关更多信息，请访问 highfieldbio.com.

媒体联系方式：

丹·埃拉米安

Opus 生物技术通讯

danieleramian@comcast.net

425-306-8716